BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37962494)

  • 1. Neighborhood Health and Outcomes in Idiopathic Pulmonary Fibrosis.
    DeDent AM; Collard HR; Thakur N
    Ann Am Thorac Soc; 2024 Mar; 21(3):402-410. PubMed ID: 37962494
    [No Abstract]   [Full Text] [Related]  

  • 2. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].
    Sun D; Cheng Z; Jiang TC; Li PF; Jia LQ; Wang TT; Zheng CP; Li Y; Duo MJ
    Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(10):748-752. PubMed ID: 32192286
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
    Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
    Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.
    Jo HE; Glaspole I; Moodley Y; Chapman S; Ellis S; Goh N; Hopkins P; Keir G; Mahar A; Cooper W; Reynolds P; Haydn Walters E; Zappala C; Grainge C; Allan H; Macansh S; Corte TJ
    BMC Pulm Med; 2018 Jan; 18(1):19. PubMed ID: 29370786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry.
    O'Brien EC; Hellkamp AS; Neely ML; Swaminathan A; Bender S; Snyder LD; Culver DA; Conoscenti CS; Todd JL; Palmer SM; Leonard TB;
    Chest; 2020 May; 157(5):1188-1198. PubMed ID: 31954102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in Clinical Characteristics and Outcomes Between Men and Women With Idiopathic Pulmonary Fibrosis: A Multicenter Retrospective Cohort Study.
    Zaman T; Moua T; Vittinghoff E; Ryu JH; Collard HR; Lee JS
    Chest; 2020 Jul; 158(1):245-251. PubMed ID: 32084394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medium-long term prognosis prediction for idiopathic pulmonary fibrosis patients based on quantitative analysis of fibrotic lung volume.
    Du K; Zhu Y; Mao R; Qu Y; Cui B; Ma Y; Zhang X; Chen Z
    Respir Res; 2022 Dec; 23(1):372. PubMed ID: 36550474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple breath washout: A new and promising lung function test for patients with idiopathic pulmonary fibrosis.
    Nyilas S; Schreder T; Singer F; Poellinger A; Geiser TK; Latzin P; Funke M
    Respirology; 2018 Aug; 23(8):764-770. PubMed ID: 29573509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implication of 1-year decline in diffusing capacity in newly diagnosed idiopathic pulmonary fibrosis.
    Lee H; Kim SY; Park YS; Choi SM; Lee JH; Park J
    Sci Rep; 2024 Apr; 14(1):8857. PubMed ID: 38632477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease.
    Goobie GC; Ryerson CJ; Johannson KA; Schikowski E; Zou RH; Khalil N; Marcoux V; Assayag D; Manganas H; Fisher JH; Kolb MRJ; Gibson KF; Kass DJ; Zhang Y; Lindell KO; Nouraie SM
    Am J Respir Crit Care Med; 2022 Feb; 205(4):459-467. PubMed ID: 34818133
    [No Abstract]   [Full Text] [Related]  

  • 11. Lung function trajectories in patients with idiopathic pulmonary fibrosis.
    Neely ML; Hellkamp AS; Bender S; Todd JL; Liesching T; Luckhardt TR; Oldham JM; Raj R; White ES; Palmer SM
    Respir Res; 2023 Aug; 24(1):209. PubMed ID: 37612608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of deep learning-based fibrosis quantification on chest CT in idiopathic pulmonary fibrosis.
    Nam JG; Choi Y; Lee SM; Yoon SH; Goo JM; Kim H
    Eur Radiol; 2023 May; 33(5):3144-3155. PubMed ID: 36928568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry.
    Case AH; Hellkamp AS; Neely ML; Bender S; Dilling DF; Gulati M; Hotchkin DL; Huie TJ; Lancaster L; Snyder LD; Conoscenti CS; Palmer SM
    Ann Am Thorac Soc; 2020 Jun; 17(6):699-705. PubMed ID: 32040340
    [No Abstract]   [Full Text] [Related]  

  • 15. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
    Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
    Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry.
    Snyder L; Neely ML; Hellkamp AS; O'Brien E; de Andrade J; Conoscenti CS; Leonard T; Bender S; Gulati M; Culver DA; Kaner RJ; Palmer S; Kim HJ;
    Respir Res; 2019 May; 20(1):105. PubMed ID: 31142314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic pulmonary fibrosis: new insights on functional characteristics at diagnosis.
    Cortes-Telles A; Forkert L; O'Donnell DE; Moran-Mendoza O
    Can Respir J; 2014; 21(3):e55-60. PubMed ID: 24712014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated airway quantification associates with mortality in idiopathic pulmonary fibrosis.
    Cheung WK; Pakzad A; Mogulkoc N; Needleman S; Rangelov B; Gudmundsson E; Zhao A; Abbas M; McLaverty D; Asimakopoulos D; Chapman R; Savas R; Janes SM; Hu Y; Alexander DC; Hurst JR; Jacob J
    Eur Radiol; 2023 Nov; 33(11):8228-8238. PubMed ID: 37505249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of angiopoietin-1 and -2 on clinical course of idiopathic pulmonary fibrosis.
    Uehara M; Enomoto N; Mikamo M; Oyama Y; Kono M; Fujisawa T; Inui N; Nakamura Y; Suda T
    Respir Med; 2016 May; 114():18-26. PubMed ID: 27109807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
    JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.